Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
NGen
NGen
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
PolTREG’s type-1 diabetes cell therapy demonstrates long-term safety and efficacy
The company’s lead asset PTG-007 exhibited a favourable safety and efficacy in paediatric patients over a 12 year period
BIO debrief: the biotech innovation highlights
Purolite’s Senior Global Director and Field Applications Scientist for Purification, Felix Solamo, discusses the highlights of the BIO 2024 trade show and where he thinks the...
Bio-Rad Launches ddSEQ Single-Cell 3' RNA-Seq Kit for Single-Cell Gene Expression
Innovative and affordable solutions for single-cell transcription and gene expression studies
Abzena and Argonaut collaborate on end-to-end biopharma drug development initiative
The companies will integrate their capabilities to provide an end-to-end drug development programme for the biopharma industry, which is controlled by a single team for...
Upcoming event
CPhI South East Asia 2024
10-12 July 2024 | Exhibition and Conference | Bangkok, Thailand
See all
Related Content
Research & Development
NGen contributes to C$4.2m Canadian viral vector manufacturing project
Canadian non-profit that matches manufacturers with new technologies will provide C$1.89m for iVexSol Canada to develop an advanced manufacturing process for lentiviral vector
Subscribe now